A PHASE-II CLINICAL-TRIAL OF MEFLOQUINE IN PATIENTS WITH CHLOROQUINE-RESISTANT FALCIPARUM-MALARIA IN THAILAND

  • 1 January 1983
    • journal article
    • research article
    • Vol. 61  (2) , 299-305
Abstract
A double-blind, randomized, dose-finding, phase II mefloquine trial was carried out in 147 adult male patients suffering from acute, uncomplicated, falciparum malaria and admitted to the Hospital for Tropical Diseases, Bangkok [Thailand], between Jan. 1980 and April 1981. Mefloguine was administered as a single oral dose of 500, 750, or 1000 mg (base) in the form of the hydrochloride. The clinical and parasitological responses were satisfactory with the 3 dosage regimens. The cure rates for the 1000, 750, and 500 mg doses were 100, 92.5 and 95%, respectively, over an observation period of 63 days. The side-effects, which were transient and generally mild, included nausea, vomiting and diarrhea. No significant changes were noted in hematological or biochemical parameters in any of the 3 groups. Sinus bradycardia, which started 4-7 days after drug administration and lasted for a few weeks, was seen in 10 patients. It was symptomless and needed no treatment. Acute brain syndrome was observed in one patient on day 21 after receiving a 1000-mg dose of mefloquine. Mefloquine was well tolerated in 1 case of acute renal failure, in 10 cases of moderately severe malaria with jaundice, in 13 cases with G-6-P dehydrogenase deficiency, and in 1 case of thalassemia. Mefloquine showed no effect on either gametocytes of Plasmodium falciparum or tissue forms of P. vivax. Mefloquine hydrochloride was found to be an effective drug for the treatment of falciparum malaria and tended to produce a more rapid clinical and parasitological response at the highest tested dose of 1000 mg (base).